• The company keeps its promises, takes social responsibility, and works with customers around the world to create long-term value for all stakeholders.
• The company has made significant progress on climate change, reducing the intensity of Scope 1 and Scope 2 greenhouse gas emissions by 29% compared to the 2020 base year.
• The company achieved the water saving target of reducing water density by 18% by 2025 ahead of schedule, and further upgraded the target to 30%.
• The company has more than 12,000 employees from 56 countries around the world, with women accounting for 53% of employees in science, technology, engineering and mathematics (STEM) positions.
• The company has been widely recognized by mainstream ESG rating agencies and maintains an ESG leadership position in the industry.

HONG KONG, April 30, 2024 /PRNewswire/ -- WuXi Biologics (2269.HK), the world's leading contract research, development and production CRDMO service company, released the 2023 “Environmental, Social and Governance (ESG) Report”, showing the substantial progress the company has made in sustainable development over the past year.

Yao Ming Biotech's ESG strategy has always been guided by the company's vision and mission, and is fully integrated into the company's global business operations. In 2023, Yao Ming Biotech joined the UN Global Compact to fulfill its commitment to the sustainable development of enterprises and society. In addition, due to its outstanding progress in the ESG field, Yao Ming Biotech has been widely recognized by mainstream ESG rating agencies, including being selected for the S&P Dow Jones Sustainability World Index and Emerging Markets Index, receiving an AAA rating in the MSCI ESG rating, receiving a “Platinum” medal from EcoVadis, an internationally authoritative sustainable development evaluation agency, being awarded Morningstar Sustainalytics's “Industry Highest Rating” and “Regional (Asia Pacific) Highest Rating” company for four consecutive years, and receiving CDP Climate Change Leadership Level Score A-.

CEO of Yao Ming Biotech,ESGChairman of the Committee Dr. Chan Chi-singHe said, “The United Nations Global Compact is the world's largest international organization promoting corporate social responsibility and sustainable development. As a member of this organization, Pharmaceutical Biotech has always regarded sustainable development as the cornerstone of its business development strategy. In 2023, opportunities and challenges coexist in the biomedical industry. With its unique CRDMO business model, Yao Ming Biotech achieved steady business growth. The company abides by its promises, bravely assumes social responsibility, cooperates with customers around the world, and continues to create positive environmental and social benefits at every step of the industrial value chain.”

Yao Ming Biotech's 2023 ESG Report comprehensively and transparently explains the company's ESG strategy and outstanding progress on major topics such as employees, global partners, community, and the environment.

Strengthening corporate governance

Under the leadership of the ESG strategy, Yao Ming Biotech has established a complete ESG governance structure, including an ESG committee composed of board members to perform supervisory duties, an ESG steering group that provides key insights, an ESG dedicated department to effectively promote strategy implementation, and special working groups on key topics. The company upholds the highest standards of integrity and business ethics, and has a zero-tolerance policy on business ethics issues. In 2023, the company established the Ethics and Compliance Committee as the highest management body of the compliance system to further enhance the ability to prevent and respond to compliance risks. Furthermore, the company actively embraces the United Nations Sustainable Development Goals, formulates a scientifically reasonable and quantifiable ESG target matrix and roadmap, continuously tracks progress, and continuously optimizes.

Actively respond to climate change

Pursuing environmental sustainability has become the only way for responsible corporate citizens to achieve long-term sustainable development. In 2023, Yao Ming Biotech officially signed the Scientific Carbon Target Initiative (SBTi) commitment to embark on a new journey of net zero emissions. The company actively reduces carbon emissions and addresses climate change through a series of substantial measures. Compared to the 2020 base year, the intensity of Scope 1 and Scope 2 greenhouse gas emissions decreased by 29% in 2023. Furthermore, the company has also achieved outstanding performance in the field of water resources management. In 2023, the company achieved the water saving target of reducing water density by 18% by 2025, using 2019 as the base year ahead of schedule, and further upgraded the target to 30%.

Building a sustainable value chain

Adhering to the principle of openness and transparency, Yao Ming Biotech always closely communicates with all stakeholders. The company selects supply chain business partners in strict accordance with the Pharmaceutical Bioethical Code of Conduct, and incorporates environmental and social sustainability performance into the supplier evaluation system. Pharmaceutical Biotech works closely with supply chain business partners to share best practices through strict entry screening, regular assessments and audits, and continuous training to create a positive impact throughout the value chain.

Promoting a culture of diversity, equality and inclusion

Talent is a key force in the development of Pharmaceutical Biotech's business. The company currently has more than 12,000 employees with professional skills and dedication. They come from 56 countries and regions with diverse cultural backgrounds. To continue to promote inclusion, equality and diversity (DEI), the company established a DEI committee composed of employee representatives from different departments and backgrounds to develop and monitor DEI strategy and implementation. The company encourages women to achieve greater career development in STEM (science, technology, engineering, and mathematics) fields. In 2023, the proportion of women in STEM positions at Pharmaceutical Biotech reached 53%, far exceeding the industry average.

Implementing corporate social responsibility

Community feedback is an essential part of Pharmaceutical Biotech's corporate social responsibility. In 2023, the total number of hours volunteered by the company's employees exceeded 8,000 hours. Leveraging technological advantages, empowering global customers, and benefiting patients is one of the three pillars of Pharmaceutical Biotech's corporate social responsibility. Yao Ming Biotech actively empowers customers around the world to develop rare disease drugs. Currently, there are 19 rare disease projects on the company's integrated platform. In 2023, Pharmaceutical Biotech successfully enabled customers to launch an innovative Pompeii disease treatment in the European Union, the United Kingdom, and the US. To celebrate this milestone, Yao Ming Biotech launched the “Run for Health” charity health run campaign to provide scholarship support for rare disease students. More than 1,500 employee volunteers from ten bases around the world participated in the event, gathering trickles into new hope.

CRDMOGreen and low carbon solutions

In order to continuously drive technological innovation and accelerate the environmentally friendly and low-carbon transformation of the global biopharmaceutical industry, Yao Ming Biotech incorporates ESG concepts into various self-developed innovation platforms such as WuxiBody, WuxiUP, and WuxiUI to provide global customers with end-to-end green and low-carbon CRDMO solutions throughout drug discovery, development and production. At the same time, with lean management and improvement tools, the company completed more than 150 ESG lean improvement projects in 2023, improving operational efficiency, reducing resource consumption, and achieving a double harvest of environmental and economic benefits.

Dr. Chen ZhishengHe said, “We are very proud that we have made so many successful developments on the way to our ESG goals. More importantly, the outstanding results we have worked to achieve can create well-being for more people. Looking forward to 2024, we will maintain our faith, forge ahead courageously, always incorporate the concept of sustainable development into business development, and continuously empower global customers to develop innovative drugs, benefit patients, and contribute to human health.”

To view the full 2023 Environmental, Social and Governance Report of Pharmaceutical Biotech, please visit:

About Yao Ming Biology

Medicinal Biotech (stock code: 2269.HK) is a leading global contract research, development and production (CRDMO) company. Through an open and integrated biopharmaceutical capability and technology empowerment platform, the company provides a full range of end-to-end services to help partners discover, develop and produce biopharmaceuticals, achieve the whole process from concept to commercial production, accelerate the global biopharmaceutical research and development process, reduce R&D costs, and benefit patients.

Yao Ming Biotech has more than 12,000 employees in China, the US, Ireland, Germany and Singapore. Through Pharmaceutical Biotech's professional service team, as well as advanced technology and deep insight, the company provides customers with efficient and economical biopharmaceutical solutions. By the end of December 2023, Yao Ming Biotech helped customers develop and produce 698 comprehensive projects, including 24 commercial production projects.

Pharmacology regards environmental, social and governance (ESG) as an important part of business development and corporate spirit, and is committed to becoming an ESG leader in the global biopharmaceutical CRDMO field, such as applying greener and more environmentally friendly next-generation biopharmaceutical technology and energy to lead the development of the industry. The company set up an ESG committee headed by the CEO to fully implement the ESG strategy and fulfill its commitment to sustainable development. For more information, please visit:.